Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-RM26-RGD
- Development stage
- Phase 1
- Lead developer
- Peking Union Medical College Hospital
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
**68Ga-RM26-RGD** is an investigational dual-target positron-emission tomography imaging radiopharmaceutical developed by Peking Union Medical College Hospital. It is a gallium-68-labeled heterodimeric peptide comprising the GRPR-targeting antagonist RM26 and an RGD motif that binds integrin alpha-V beta-3. Following intravenous administration, it is intended to visualize tumors that express gastrin-releasing peptide receptor on tumor cells and/or integrin alpha-V beta-3 in tumor-associated neovasculature. The agent is being evaluated by PET/CT in breast cancer, prostate cancer, and brain tumors, including comparison with 18F-FDG PET/CT and single-target 68Ga-RM26 or 68Ga-RGD imaging. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05549024))
- Other names
- 68Ga-DOTA-RM26-RGD[68Ga]Ga-DOTA-RM26-RGD
02
Targets
αVβ3 (Integrin αVβ3)GRPR (Gastrin-releasing peptide receptor)
Beyond the preview
Go deeper on 68Ga-RM26-RGD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-RM26-RGD.